Skip to main content
SpringerLink
Log in

Menopausal Health after Breast Cancer

  • Chapter
Breast Cancer

Part of the book series: M. D. Anderson Cancer Care Series ((MDCCS))

  • 235 Accesses

Abstract

The gradual decline in estrogen production that follows menopause often contributes to significant climacteric symptoms, accelerated bone loss, and cardiovascular morbidity. Estrogen replacement can prevent or reverse many postmenopausal morbidities and has been widely used for several decades. The concern that researchers in early studies may have been hasty in their conclusions about the safety of estrogen replacement has prompted the reassessment of old data and further analyses of large groups of women. These new analyses take into consideration age, estrogen formulation, and duration of estrogen administration as risk factors for breast cancer. An emerging consensus is that very prolonged estrogen use may contribute to breast cancer risk. The suggestion that women who have previously undergone treatment for breast cancer should not receive exogenous estrogen has constituted one area of general agreement for many years. Accordingly, alternative strategies have been developed to address postmenopausal health needs for breast cancer survivors. However, this proscription has been challenged in recent years because both the population characteristics and health needs of women with a prior diagnosis of breast cancer have been changing. Recent information about the outcome of women who elect to take estrogen after breast cancer as well as those who develop breast cancer while taking estrogen is contributing to the emerging opinion that decisions regarding estrogen may be individualized in some cases.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 59.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Suggested Readings

  • Bergkvist L, Adami HO, Persson I, Bergstrom R, Krusemo UB. Prognosis after breast cancer diagnosis in women exposed to estrogen and estrogen-progestogen replacement therapy. Am J Epidemiol 1989; 130: 221–228.

    PubMed  CAS  Google Scholar 

  • Bluming AZ, Waisman JR, Dosik GM, et al. Hormone replacement therapy (HRT) in women with previously treated primary breast cancer. Update II. Proceedings of the American Society of Clinical Oncology 1997; 16: 131A.

    Google Scholar 

  • Bonnier P, Bessenay F, Sasco AJ, et al. Impact of menopausal hormone-replacement therapy on clinical and laboratory characteristics of breast cancer. Int J Cancer 1998; 79: 278–282.

    Article  PubMed  CAS  Google Scholar 

  • Couzi RJ, Helzlsouer KJ, Fetting JH. Prevalence of menopausal symptoms among women with a history of breast cancer and attitudes toward estrogen replacement therapy. J Clin Oncol 1995; 13: 2737–2744.

    PubMed  CAS  Google Scholar 

  • Decker D, Cox T, Burdakin I, et al. Hormone replacement therapy (HRT) in breast cancer survivors. Proceedings of the American Society of Clinical Oncology 1996; 15: 136A.

    Google Scholar 

  • Delmas PD, Bjarnason NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997; 337: 1641–1647.

    Article  PubMed  CAS  Google Scholar 

  • DiSaia PJ, Grosen EA, Kurosaki T, Gildea M, Cowan B, Anton-Culver H. Hormone replacement therapy in breast cancer survivors: a cohort study. Am J Obstet Gynecol 1996; 174: 1494–1498.

    Article  PubMed  CAS  Google Scholar 

  • Dupont WD, Page DL, Rogers LW, Parl FE Influence of exogenous estrogens, proliferative breast disease, and other variables on breast cancer risk. Cancer 1989; 63: 948–957.

    Article  PubMed  CAS  Google Scholar 

  • Eden JA, Bush T, Nand S. A case-control study of combined continuos estrogenprogestin replacement therapy among women with a personal history of breast cancer. Menopause 1995; 2: 67–72.

    Article  Google Scholar 

  • Fornander T, Rutqvist LE, Sjoberg HE, Blomqvist L, Maltsson A, Glas U. Longterm adjuvant tamoxifen in early breast cancer: effect on bone mineral density in postmenopausal women. J Clin Oncol 1990; 8: 1019–1024.

    PubMed  CAS  Google Scholar 

  • Fowble B, Hanlon A, Freedman G, et al. Postmenopausal hormone replacement therapy: effect on diagnosis and outcome in early-stage invasive breast cancer treated with conservative surgery and radiation. J Clin Oncol 1999; 17: 1680 1688.

    Google Scholar 

  • Gapstur SM, Morrow M, Sellers TA. Hormone replacement therapy and risk of breast cancer with a favorable histology: results of the Iowa Women’s Health Study. JAMA 1999; 281: 2091–2097.

    Article  PubMed  CAS  Google Scholar 

  • Goldberg RM, Loprinzi CL, O’Fallon JR, et al. Transdermal clonidine for ameliorating tamoxifen-induced hot flushes. J Clin Oncol 1994; 12: 155–158.

    PubMed  CAS  Google Scholar 

  • Gorins A, Cremieu A, Espie M, et al. Hormone replacement therapy (HRT) in women with previously treated primary breast cancer. Update III. Proceedings of the American Society of Clinical Oncology 1997; 5: 131A.

    Google Scholar 

  • Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992; 117: 1016–1037.

    Article  PubMed  CAS  Google Scholar 

  • Greendale GA, Judd HL. The menopause: health implications and clinical management. J Am Geriatr Soc 1993; 41: 426–436.

    PubMed  CAS  Google Scholar 

  • Grodstein F, Stampfer MJ, Colditz GA, et al. Postmenopausal hormone therapy and mortality. New Engl J Med 1997; 336: 1769–1775.

    Article  PubMed  CAS  Google Scholar 

  • Guidozzi F. Estrogen replacement therapy in breast cancer survivors. Int J Gynaecol Obstet 1999; 64: 59–63.

    Article  PubMed  CAS  Google Scholar 

  • Harding C, Knox WF, Faragher EB, Baildam A, Bundred NJ. Hormone replacement therapy and tumour grade in breast cancer: prospective study in screening unit. BMJ 1996; 312: 1646–1647.

    Article  PubMed  CAS  Google Scholar 

  • Hodgson SF, Johnston CC. AACE Clinical Practice Guidelines for the Prevention and Treatment of Postmenopausal Osteoporosis. Endocrine Practice 1996; 2: 155170.

    Google Scholar 

  • Holli K, Isola J, Cuzick J. Low biologic aggressiveness in breast cancer in women using hormone replacement therapy. J Clin Oncol 1998; 16: 3115–3120.

    PubMed  CAS  Google Scholar 

  • Hormone Foundation, Canadian Breast Cancer Research Initiative, National Cancer Institute of Canada, Endocrine Society, and the University of Virginia Cancer Center and Women’s Place. Treatment of estrogen deficiency symptoms in women surviving breast cancer. J Clin Endocrinol Metab 1998; 83: 1993–2000.

    Article  Google Scholar 

  • Hunt K, Vessey M, McPherson K. Mortality in a cohort of long-term users of hormone replacement therapy: an updated analysis. Br J Obstet Gynaecol 1990; 97: 1080–1086.

    Article  PubMed  CAS  Google Scholar 

  • Jernstrom H, Frenander J, Ferno M, Olsson H. Hormone replacement therapy before breast cancer diagnosis significantly reduces the overall death rate compared with never-use among 984 breast cancer patients. Br J Cancer 1999; 80: 1453–1458.

    Article  PubMed  CAS  Google Scholar 

  • Loprinzi CL, Michalak JC, Quella SK, et al. Megestrol acetate for the prevention of hot flashes. N Engl J Med 1994; 331: 347–352.

    Article  PubMed  CAS  Google Scholar 

  • Love RR, Wiebe DA, Newcomb PA, et al. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women. Ann Intern Med 1991; 115: 860–864.

    Article  PubMed  CAS  Google Scholar 

  • Magnusson C, Holmberg L, Norden T, Lindgren A, Persson I. Prognosis characteristics in breast cancers after hormone replacement therapy. Breast Cancer Res Treat 1996; 38: 325–334.

    Article  PubMed  CAS  Google Scholar 

  • Marsden J, Sacks NPM. Hormone replacement therapy and breast cancer. Endocrine-Related Cancer 1997; 4: 269–279.

    Article  CAS  Google Scholar 

  • Peters GN, Jones SE. Estrogen replacement therapy in breast cancer patients. A time for change? Proceedings of the American Society of Clinical Oncology 1996; 15: 121A.

    Google Scholar 

  • Powles TJ, Hickish T, Casey S, O’Brien M. Hormone replacement after breast cancer. Lancet 1993; 342: 60–61.

    Article  PubMed  CAS  Google Scholar 

  • Rutqvist LE, Mattsson A. The Stockholm Breast Cancer Study Group. Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen. J Natl Cancer Inst 1993; 85: 1398–1406.

    Article  PubMed  CAS  Google Scholar 

  • Schairer C, Gail M, Byrne C, et al. Estrogen replacement therapy and breast cancer survival in a large screening study. J Natl Cancer Inst 1999; 91: 264–270.

    Article  PubMed  CAS  Google Scholar 

  • Sellers TA, Mink PJ, Cerhan JR, et al. The role of hormone replacement therapy in the risk for breast cancer and total mortality in women with a family history of breast cancer. Ann Intern Med 1997; 127: 973–980.

    Article  PubMed  CAS  Google Scholar 

  • Speroff L, Glass RH, Kase NG. Menopause and postmenopausal hormone therapy. In: Clinical Gynecologic Endocrinology and Infertility. 5th Ed. Baltimore: Williams and Wilkins; 1994: 583–650.

    Google Scholar 

  • Squitieri R, Tartter PI, Ahmed S, Brower ST, Theise ND. Carcinoma of the breast in postmenopausal hormone user and nonuser control groups. J Am Coll Surg 1994; 178: 167–170.

    PubMed  CAS  Google Scholar 

  • Strickland DM, Gambrell RD Jr, Butzin CA, Strickland K. The relationship between breast cancer survival and prior postmenopausal estrogen use. Obstet Gynecol 1992; 80: 400–404.

    PubMed  CAS  Google Scholar 

  • Utian WH, Schiff I. NAMS-Gallup Survey on women’s knowledge, information sources, and attitudes to menopause and hormone replacement therapy. Menopause 1994; 1: 39–48.

    Article  Google Scholar 

  • Vassilopoulou-Sellin R, Asmar L, Hortobagyi GN, et al. Estrogen replacement therapy after localized breast cancer: clinical outcome of 319 women followed prospectively. J Clin Oncol 1999; 17: 1482–1487.

    PubMed  CAS  Google Scholar 

  • Vassilopoulou-Sellin R, Theriault R, Klein MJ. Estrogen replacement therapy in women with prior diagnosis and treatment for breast cancer. Gynecol Oncol 1997; 65: 89–93.

    Article  PubMed  CAS  Google Scholar 

  • Vassilopoulou-Sellin R, Zolinski C. Estrogen replacement therapy in women with breast cancer: a survey of patient attitudes. Am J Med Sci 1992; 304: 145–149.

    Article  PubMed  CAS  Google Scholar 

  • Willis DB, Calle EE, Miracle-McMahill HL, Heath CW Jr. Estrogen replacement therapy and risk of fatal breast cancer in a prospective cohort of postmenopausal women in the United States. Cancer Causes Control 1996; 7: 449–457.

    Article  PubMed  CAS  Google Scholar 

  • Yuen J, Persson I, Berkvist L, Hoover R, Schairer C, Adami HO. Hormone replacement therapy and breast cancer mortality in Swedish women: results after adjustment for ‘healthy drug-user’ effect. Cancer Causes Control 1993; 4: 369–374.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Rena Vassilopoulou-Sellin
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Surgical Oncology, M. D. Anderson Cancer Center, The University of Texas, 77030-4009, Houston, TX, USA

    Kelly K. Hunt M.D.

  2. Department of Plastic Surgery, M. D. Anderson Cancer Center, The University of Texas, 77030-4009, Houston, TX, USA

    Geoffrey L. Robb M.D.

  3. Department of Radiation Oncology, M. D. Anderson Cancer Center, The University of Texas, 77030-4009, Houston, TX, USA

    Eric A. Strom M.D.

  4. Department of Blood and Marrow Transplantation, M. D. Anderson Cancer Center, The University of Texas, 77030-4009, Houston, TX, USA

    Naoto T. Ueno M.D., Ph.D.

Rights and permissions

Reprints and permissions

Copyright information

© 2001 Springer Science+Business Media New York

About this chapter

Cite this chapter

Vassilopoulou-Sellin, R. (2001). Menopausal Health after Breast Cancer. In: Hunt, K.K., Robb, G.L., Strom, E.A., Ueno, N.T. (eds) Breast Cancer. M. D. Anderson Cancer Care Series. Springer, New York, NY. https://doi.org/10.1007/978-0-387-21842-7_17

Download citation

  • DOI: https://doi.org/10.1007/978-0-387-21842-7_17

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-0-387-95190-4

  • Online ISBN: 978-0-387-21842-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation